PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation
NYSE:MD • US58502B1061
Current stock price
20.5 USD
-0.48 (-2.29%)
At close:
20.5 USD
0 (0%)
After Hours:
This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MD Profitability Analysis
1.1 Basic Checks
- In the past year MD was profitable.
- MD had a positive operating cash flow in the past year.
- In multiple years MD reported negative net income over the last 5 years.
- MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- MD has a Return On Assets of 7.36%. This is amongst the best in the industry. MD outperforms 87.00% of its industry peers.
- MD has a Return On Equity of 19.10%. This is amongst the best in the industry. MD outperforms 86.00% of its industry peers.
- MD has a Return On Invested Capital of 9.88%. This is in the better half of the industry: MD outperforms 80.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.85%.
- The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- Looking at the Profit Margin, with a value of 8.64%, MD belongs to the top of the industry, outperforming 91.00% of the companies in the same industry.
- In the last couple of years the Profit Margin of MD has grown nicely.
- MD has a better Operating Margin (12.07%) than 84.00% of its industry peers.
- MD's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MD Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
- The number of shares outstanding for MD has been reduced compared to 1 year ago.
- The number of shares outstanding for MD has been reduced compared to 5 years ago.
- MD has a better debt/assets ratio than last year.
2.2 Solvency
- MD has an Altman-Z score of 2.06. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score of 2.06. This is comparable to the rest of the industry: MD outperforms 52.00% of its industry peers.
- The Debt to FCF ratio of MD is 2.36, which is a good value as it means it would take MD, 2.36 years of fcf income to pay off all of its debts.
- MD has a better Debt to FCF ratio (2.36) than 74.00% of its industry peers.
- MD has a Debt/Equity ratio of 0.66. This is a neutral value indicating MD is somewhat dependend on debt financing.
- MD has a Debt to Equity ratio of 0.66. This is comparable to the rest of the industry: MD outperforms 55.00% of its industry peers.
- Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2.06 |
ROIC/WACC1.18
WACC8.37%
2.3 Liquidity
- A Current Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
- With a decent Current ratio value of 1.66, MD is doing good in the industry, outperforming 68.00% of the companies in the same industry.
- MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a better Quick ratio (1.66) than 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. MD Growth Analysis
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
- MD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.01% yearly.
- MD shows a decrease in Revenue. In the last year, the revenue decreased by -4.92%.
- Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 1.99% on average per year.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- The Earnings Per Share is expected to grow by 0.99% on average over the next years.
- The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MD Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 10.10, which indicates a very decent valuation of MD.
- MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 91.00% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 24.88. MD is valued rather cheaply when compared to this.
- MD is valuated reasonably with a Price/Forward Earnings ratio of 8.91.
- Based on the Price/Forward Earnings ratio, MD is valued cheaper than 93.00% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.19. MD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.1 | ||
| Fwd PE | 8.91 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 88.00% of the companies in the same industry.
- MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.74 | ||
| EV/EBITDA | 6.78 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.76
PEG (5Y)1.01
EPS Next 2Y8.67%
EPS Next 3Y4.87%
5. MD Dividend Analysis
5.1 Amount
- No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MD Fundamentals: All Metrics, Ratios and Statistics
20.5
-0.48 (-2.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)05-04 2026-05-04/bmo
Inst Owners102.64%
Inst Owner Change1.24%
Ins Owners1.94%
Ins Owner Change-0.8%
Market Cap1.70B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (6.98%)
Short Float %3.35%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-5.15%
PT rev (3m)-5.15%
EPS NQ rev (1m)-1.3%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)2.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)-1.72%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-1.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.1 | ||
| Fwd PE | 8.91 | ||
| P/S | 0.89 | ||
| P/FCF | 6.74 | ||
| P/OCF | 6.28 | ||
| P/B | 1.97 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.78 |
EPS(TTM)2.03
EY9.9%
EPS(NY)2.3
Fwd EY11.23%
FCF(TTM)3.04
FCFY14.85%
OCF(TTM)3.27
OCFY15.93%
SpS23.06
BVpS10.43
TBVpS-4.96
PEG (NY)0.76
PEG (5Y)1.01
Graham Number21.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.06 |
F-Score8
WACC8.37%
ROIC/WACC1.18
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.1 and the Price/Book (PB) ratio is 1.97.